Below is a look at some of the headlines for companies that made news in the healthcare sector on May 15, 2013.{ nfg} Gilead Sciences, Inc. announced results from a Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with treatment-nave chronic lymphocyt
By a News Reporter-Staff News Editor at Biotech Week ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013, at
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral presentation at the 12th International Symposium on...
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral presentation at the 12th International Symposium on...
By a News Reporter-Staff News Editor at Biotech Week Toltec Pharmaceuticals, Llc has been issued patent application serial number 709740, according to news reporting originating out of Washington, D.C., by NewsRx editors. This patent application was filed on December 10, 2012 and was made available online on May 2, 2013. Unfortunately, national s
*Algeta to host international conference call scheduled for tomorrow at 08:00 CET, 02:00 Eastern time- details below. Oslo, Norway, 15 May 2013- Algeta ASA announces that Bayer has received US Food and Drug Administration approval for Xofigo injection for the treatment of patients with castration- resistant prostate cancer, symptomatic bone metasta
Not Intended for US Media* New treatment for castration-resistant prostate cancer patients with bone metastases* Xofigo shown in a pivotal phase III trial to significantly improve overall survival* Algeta to host international conference call scheduled for tomorrow at 08:00 CET- details below Oslo, Norway, 15 May 2013- Algeta ASA announces that the
Array BioPharma Inc. today announced presentations on its MEK inhibitors, MEK162 and selumetinib at the 2013 American Society of Clinical Oncology Annual Meeting, which will be held May 31 June 4, 2013 in Chicago, Illinois. ASCO's embargo for the abstract discussing the Phase 2 results of selumetinib versus temozolomide in uveal melanoma will li
Location: Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services. Classification Code: B- Special studies and analysis- not R&D. Subject: Statistical Evaluation and Design, Conduct and Analysis of Clinical Studies for Therapeutic Biologic Products Regulated by CBER.
WAYNE, N.J., May 15, 2013/ PRNewswire/ Bayer HealthCare announced today that patient enrollment is underway for RESORCE, an international Phase III trial to evaluate the efficacy and safety of Stivarga tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar tablets, an anticancer medicine for the t
WAYNE, N.J., May 15, 2013/ PRNewswire/ Intended for U.S. Algeta US, LLC and Bayer Healthcare will co-promote the product in the U.S. "Most men with castration-resistant prostate cancer develop bone metastases, which can decrease overall survival," said Oliver Sartor, MD, North American Principal Investigator for the pivotal trial and medical dir
Bio-Path Holdings, Inc. is a development stage company with its lead cancer drug candidate, Liposomal Grb-2, currently in clinical trials. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company's current delivery technology to improve further the effectivenes
When you read this section of this Quarterly Report on Form 10- Q, it is important that you also read the condensed consolidated financial statements and related notes included elsewhere in this Form 10- Q and in conjunction with our Annual Report on Form 10- K for the fiscal year ended September 30, 2012. Our actual results could differ materially
Boehringer Ingelheim Pharmaceuticals, Inc. today announced data from two Phase III clinical trials involving two different investigational oncology compounds afatinib* and nintedanib* in two distinct patient populations with advanced non-small cell lung cancer. Results from both studies will be presented at the 49 th Annual Meeting of the Ame
Boston Therapeutics, Inc., a pharmaceutical company developing and commercializing complex carbohydrate-based drugs to treat diabetes and inflammatory diseases, announced its financial results for the three months ended March 31, 2013. "During this quarter, we continued our growth as a drug discovery, development and commercialization company, and
May 15 Tokai Pharmaceuticals Inc. said today it has raised $35.5 million in a fifth round of funding based on "encouraging clinical progress and investor support" for the Cambridge- based biopharmaceutical company's lead prostate cancer drug candidate, galeterone. The financing round included both current investors, Apple Tree Partners and Novart
Dublin- Research and Markets has announced the addition of the "China Pharmaceutical Guidebook Series 3 2013 Edition- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products" report to their offering. -A comprehensive and thorough..
Dublin- Research and Markets has announced the addition of the "China Pharmaceutical Guidebook Series 4 2013- Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines& Natural Medicines" report to their offering.
Robert Latta, R- Ohio, issued the following news release:. The House Energy and Commerce Committee today approved legislation introduced by Congressman Bob Latta that will strengthen and secure the nation's pharmaceutical distribution supply chain. Fred Upton, approved H.R. 1919, the Safeguarding America's Pharmaceuticals Act of 2013 by a voice vot
Under Business Highlights, 3rd bullet should read: A Phase 2 study of CPX-351 in adults with untreated high-risk Myelodysplastic Syndrome and AML at high risk of treatment-related mortality was opened at the Fred Hutchinson Cancer Research Center. Celator Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing new and more...
Media Release Latest from daratumumab Phase I/II study in relapsed/refractory multiple myeloma Pre-clinical data from HuMax-TF-ADC program Abstracts available online at ASCO website Copenhagen, Denmark; May 16, 2013 Genmab A/S announced today that the latest data from the ongoing Phase I/II study of daratumumab in relapsed/refractory multi
By a News Reporter-Staff News Editor at Biotech Week Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.
Edgemont Capital Partners, a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical Research in its sale to Altasciences Group. Vince and Associates manages complex early development clinical drug trials at its state-of-the-art
We are a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop innovative targeted therapeutics designed to treat cancer and other diseases. In 2012, we refocused our clinical and regulatory strategy to leverage resources in China and to conduct clinical and regulatory...
EntreMed, Inc., a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2013.. The reported net loss for the three months ended March 31, 2012 included non-cash interest charges totaling approximately $0.9 million associated with the Company's 2012 financing, recorded in accordance with US gene
